SYSTEMS AND METHODS FOR REVERSIBLE NERVE BLOCK TO RELIEVE DISEASE SYMPTOMS
20180056074 ยท 2018-03-01
Inventors
Cpc classification
A61B18/148
HUMAN NECESSITIES
A61B5/08
HUMAN NECESSITIES
A61B2018/1467
HUMAN NECESSITIES
A61B5/0816
HUMAN NECESSITIES
A61B5/4848
HUMAN NECESSITIES
A61B5/0036
HUMAN NECESSITIES
A61B2017/00039
HUMAN NECESSITIES
A61B5/0205
HUMAN NECESSITIES
A61B5/0245
HUMAN NECESSITIES
A61B5/085
HUMAN NECESSITIES
A61B5/388
HUMAN NECESSITIES
A61B18/1492
HUMAN NECESSITIES
A61N1/37229
HUMAN NECESSITIES
A61B5/24
HUMAN NECESSITIES
A61B2090/3966
HUMAN NECESSITIES
A61B2018/00214
HUMAN NECESSITIES
International classification
A61N1/372
HUMAN NECESSITIES
A61N1/05
HUMAN NECESSITIES
Abstract
The present disclosure relates to the field of neuromodulation. Specifically, the present disclosure relates to systems and methods for reversibly blocking an electrical signal from travelling along a target nerve. In particular, the present disclosure relates to systems and methods for relieving a pulmonary symptom by reversibly blocking an electrical signal from travelling along the vagus nerve or internal branch of the superior laryngeal nerve
Claims
1. A system, comprising: an energy transmitting element; a plurality of electrodes disposed about an inner surface of the energy transmitting element, wherein the energy transmitting element is configured to be disposed about a portion of a target nerve such that at least one electrode of the plurality of electrodes contacts the target nerve; and a controller electrically coupled to each electrode of the plurality of electrodes.
2. The system of claim 1, wherein the energy transmitting element is moveable between a first configuration and a second configuration.
3. The system of claim 2, wherein at least one electrode of the plurality of electrodes is configured to contact the target nerve when the energy transmitting element is in the second configuration.
4. The system of claim 1, wherein the energy transmitting element includes a coiled lead.
5. The system of claim 1, wherein the energy transmitting element includes a cuff moveable between a first unrolled configuration and a second rolled configuration.
6. The system of claim 1, wherein the energy transmitting element includes a hook moveable from between a first extended configuration and a second retracted configuration.
7. The system of claim 1, wherein the energy transmitting element includes a cassette moveable between a first open configuration and a second closed configuration.
8. The system of claim 1, wherein each electrode of the plurality of electrodes is configured to act as one or more of a sensing electrode, mapping electrode, pacing electrode, stimulating electrode and ablation electrode.
9. The system of claim 1, wherein the controller includes an electrical activity processing system configured to measure an intrinsic electrical activity of the target nerve, wherein the intrinsic electrical activity is delivered to the electrical activity processing system from at least one electrode of the plurality of electrodes.
10. The system of claim 1, wherein the controller includes an energy source configured to deliver treatment energy to each electrode of the plurality of electrodes.
11. The system of claim 9, wherein the controller includes an energy source configured to deliver treatment energy to the electrode or electrodes of the plurality of electrodes that measured an intrinsic electrical activity of the target nerve.
12. The system of claim 10, wherein the treatment energy reduces an ability of the target nerve to send an electrical signal.
13. The system of claim 11, wherein the controller further includes a sensor configured to detect a body parameter, and wherein the controller includes an energy source configured to deliver treatment energy to the electrode or electrodes of the plurality of electrodes that measured an intrinsic electrical activity of the target nerve when the body parameter is detected.
14. A system, comprising: an energy transmitting element; a plurality of electrodes disposed about an outer surface of the energy transmitting element, wherein the energy transmitting element is configured to be disposed along a portion of a target nerve such that at least one electrode of the plurality of electrodes contacts the target nerve; and a controller electrically coupled to each electrode of the plurality of electrodes.
15. The system of claim 14, wherein the energy transmitting element includes a lead.
16. The system of claim 14, further comprising a cuff moveable between a first configuration and a second configuration, wherein the cuff is configured to be disposed about the energy transmitting element and the target nerve when in the second configuration.
17. A method of treating a nerve, comprising: positioning an energy transmitting element around or adjacent to a target nerve, wherein the energy transmitting element includes a plurality of electrodes disposed about a surface thereof; determining which electrode, or electrodes, of the plurality of electrodes are in contact with the target nerve; and delivering treatment energy from the electrode or electrodes that are in contact with the target nerve, wherein the treatment energy is sufficient to at least partially relieve a pulmonary symptom.
18. The method of claim 17, wherein the treatment energy reduces an ability of the target nerve to send an electrical signal.
19. The method of claim 17, wherein the treatment energy is delivered following the detection of a body parameter.
20. The method of claim 19, further comprising monitoring the body parameter, and altering the treatment energy based on the measured body parameter.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Non-limiting examples of the present disclosure are described by way of example with reference to the accompanying figures, which are schematic and not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the disclosure shown where illustration is not necessary to allow those of skill in the art to understand the disclosure. In the figures:
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042] It is noted that the drawings are intended to depict only typical or exemplary embodiments of the disclosure. Accordingly, the drawings should not be considered as limiting the scope of the disclosure. The disclosure will now be described in greater detail with reference to the accompanying drawings.
DETAILED DESCRIPTION
[0043] Before the present disclosure is described in further detail, it is to be understood that the disclosure is not limited to the particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting beyond the scope of the appended claims. Unless defined otherwise, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs. Finally, although embodiments of the present disclosure are described with specific reference to systems and methods for reversibly blocking an electrical signal from travelling along the vagus nerve or internal branch of the superior laryngeal nerve to relieve pulmonary symptoms, it should be appreciated that such systems and methods may be used to establish a reversible conduction block along a variety of nerves and nervous systems to treat a variety of acute or chronic symptoms. For example, a reversible conduction block of various sympathetic nerves may reduce or eliminate symptoms of pain and/or vascular tone, while blocking motor nerves may provide relief of movement disorders.
[0044] As used herein, the term distal refers to the end farthest away from a medical professional when introducing a device into a patient, while the term proximal refers to the end closest to the medical professional when introducing a device into a patient.
[0045] The systems and methods of the present disclosure are described herein with particular exemplary reference to relieving pulmonary symptoms (e.g., airway smooth muscle contraction (ASM), mucus production, etc.) by reversibly blocking parasympathetic nerves that traverse along the bronchi of the lung. It should be appreciated that reversibly blocking such nerves may reduce or control other reflexes, including, for example, chronic coughing, dyspnea and dynamic hyperinflation.
[0046] In one embodiment, the present disclosure provides an energy transmitting element comprising a plurality of electrodes spaced about an inner surface thereof. The energy transmitting element may include a variety of shapes or configurations designed to be disposed around or alongside a target nerve such that one or more of the plurality of electrodes are placed in contact with, or in the vicinity of the target nerve. To this end, the electrodes may be spaced both axially and longitudinally about the surface of the energy transmitting element. Each electrode of the plurality of electrodes may be electrically coupled to a controller by one or more conducting wires. Each of the electrodes may be configured to act as one or more of a sensing electrode, mapping electrode, pacing electrode, stimulating electrode and ablation electrode.
[0047] Referring to
[0048] Referring to
[0049] Referring to
[0050] Referring to
[0051] In another embodiment, the cassette 620 may include a securing element configured to maintain the top and bottom portions 620a, 620b of the cassette in a closed configuration around the target nerve (or anatomical feature). For example, the securing element may include a latch disposed on the top portion 620a of the cassette 620 configured to engage a corresponding post or recess disposed on the bottom portion 620b of the cassette 620. Alternatively, the top and bottom portions 620a, 620b may include corresponding apertures (e.g., suture holes) through which a suture may be tied to maintain the cassette 620 in a closed configuration.
[0052] Referring to
[0053] Referring to
[0054] Referring to
[0055] The controller may include an electrical activity processing system configured to measure the intrinsic electrical activity of a target nerve, or individual nerve fibers. The intrinsic electrical activity is delivered to the controller from the electrode or electrodes in contact with the target nerve and along the respective conducting wire(s). In one embodiment, identifying which electrode or electrodes sense or detect intrinsic electrical activity may allow the controller to identify which electrode(s) should be used to deliver treatment energy to the target nerve. The controller may further include an energy source, e.g., a radiofrequency (RF) generator, to deliver treatment energy to only those electrode(s) in contact with the target nerve (e.g., those that detected intrinsic electrical activity). It should be appreciated that the controller may be configured to provide a variety of energy delivery parameters based on the measured intrinsic electrical activity and/or the symptom which the treatment energy is meant to alleviate. In addition, the controller may continually or intermittently monitor the intrinsic electrical activity during (or after) the delivery of treatment energy, and vary the delivery parameter accordingly.
[0056] In another embodiment, a specific mapping protocol may be implemented at the time of implantation within the patient, or following a pre-determined time post-implantation, to identify the optimal electrode pairs for delivering treatment energy. For example, the IPG may deliver low frequency pulses of energy (e.g., less than approximately 20 Hz) to elicit action potentials and a resultant indicator of a symptom (e.g., bronchoconstriction). Higher frequency treatment energy (e.g., approximately 100 Hz to approximately 1 kHz) may then be delivered from the identified electrodes to facilitate neurotransmitter depletion blocking of the target nerve.
[0057] In another embodiment, a pulmonary symptom may be measured (i.e., monitored) during the systematic delivery of treatment energy to map (i.e., identify) the optimal electrode pairs required to achieve a reversible nerve block.
[0058] The controller may further include one or more physiological sensors configured to detect a body parameter (e.g., coughing, sneezing, wheezing and/or mucus production) indicative of a target symptom, and provide closed-loop smart therapy to deliver treatment energy to the electrode or electrodes previously identified as being in contact with the target nerve when an attack is detected. For example, the sensor may include an impedance sensor configured to detect or measure mucus production, airway smooth muscle (ASM) contraction, inflammation and/or elevated respiratory rate. In addition, or alternatively, the sensor may include an electrocardiogram (ECG), perfusion or blood pressure sensor configured to detect an elevated or variable heart rate, blood pressure or respiratory rate. In addition, or alternatively, the sensor could be configured to detect a change in autonomic tone, such as by detecting changes in heart rate variability (HRV). Examples of HRV parameters include standard deviation of normal-to-normal intervals (SDNN), standard deviation of averages of normal-to-normal intervals (SDANN), ratio of low-frequency (LF) to high-frequency (HF) HRV (LF/HF ratio), HRV footprint, root-mean-square successive differences (RMSSD), and percentage of differences between normal-to-normal intervals that are greater than 50 milliseconds (pNN50). In addition, or alternatively, the sensor may include an acoustic sensor configured to detect wheezing, coughing and other body sounds associated with airway obstruction or constriction. In addition, or alternatively, the sensor may include a pressure sensor configured to detect sudden pressure increases due to, e.g., coughing, wheezing or heavy breathing. For example, two or more pressure sensors may be positioned in sequence to provide an airflow sensor for measuring resistance indicative of airway constriction.
[0059] Referring to
[0060] It should be appreciated that any of the energy transmitting elements disclosed herein may be endoscopically or laparoscopically implanted using standard surgical methods practiced by cardiothoracic surgeons to access the thoracic cavity without the need for invasive thoracotomies. Alternatively, the energy transmitting element may be implanted by an interventional pulmonologist using a bronchoscope to access the airway, such that the energy transmitting element may be inserted through the airway and in close vicinity to the target nerve branch. It should be appreciated that the energy transmitting elements disclosed herein may be delivered using a variety of delivery tools as are known in the art, including, e.g., a bronchoscope, endoscope, laparoscope, catheter, guidewire or steerable catheter or guidewire.
[0061] In one embodiment, the treatment parameter required to establish a reversible conduction block of the vagus nerve, or specific nerve fibers of the vagus nerve, may include the delivery of kHz frequency energy. Such energy may be applied in a variety of continued or pulsed waveforms, including e.g., sinusoidal, rectangular and triangular. By comparison, establishing a neuromuscular conduction block typically requires repetitive stimulation in the range of approximately 100 to 900 Hz. For example, a treatment parameter of approximately 1 kHz to 50 kHz and approximately 1 mA to 40 mA applied to one or both branches of the vagus nerve for approximately 30 minutes may provide a near-immediate nerve block which lasts for approximately 90 minutes.
[0062] In one embodiment, the present disclosure also provides systems and methods to establish a reversible electrical nerve block to one or both internal branches of the superior laryngeal nerve (ib-SLN) as a treatment for symptoms of asthma, COPD and other pulmonary conditions. It should be appreciated that the ib-SLN protects the respiratory tract by mobilizing the glottis closure reflex during swallowing, coughing and vomiting. For this reason, conventional surgical procedures only target a unilateral transection of the ib-SLN. Bilateral damage of the ib-SLN might lead to phonation disorders and disorders of respiratory control. The reversible treatments of the present disclosure may therefore allow temporary bilateral therapy with superior therapeutic results.
[0063] In one embodiment, the present disclosure may involve surgically implanting any of the electrode configurations disclosed herein adjacent to, or around, one or both branches of the ib-SLN, e.g., via a minimally invasive direct-visualization technique. For example, as illustrated in
[0064] Energy may be delivered from the controller 1440 to the coiled lead 420 to establish a reversible nerve block. For example, a treatment parameter of approximately 1 kHz to 50 kHz and approximately 1 mA to 40 mA applied to one or both of the ib-SLN for approximately 30 minutes may provide a near-immediate nerve block which lasts for approximately 90 minutes. Alternatively, a reversible but substantially longer lasting (e.g., 6-9 months) effect may be achieved by delivering pulsed radiofrequency alternating current, e.g., approximately 480 kHz, to one branch of the ib-SLN. To avoid the potential phonation and respiratory control disorder discussed above, this longer lasting treatment is not delivered to both branches of the ib-SLN. This method may further entail one or more sensors configured to provide closed-loop temperature control to ensure that the temperature of the nerve and surrounding tissue does not exceed a temperature at which irreversible damage occurs to the nerve, for example, a temperature that does not exceed 45 C.
[0065] It should be appreciated that the electrodes of any of the energy transmitting elements disclosed herein may be unipolar, bipolar or multipolar. In one embodiment, a multipolar electrode may allow electronic repositioning and greater selectivity over which nerve, or nerve fibers, to stimulate. Such electrodes (leads) may be formed from materials commonly used in implantable cardiac or neurostimulation electrodes (leads) and catheters, including suitable insulative materials such as e.g., ETFE, PTFE, silicone, and PU and conductive materials such as, e.g., MP35N, stainless steel, PtIr, Nitinol, Elgiloy and the like.
[0066] All of the devices and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the devices and methods of this disclosure have been described in terms of preferred embodiments, it may be apparent to those of skill in the art that variations can be applied to the devices and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.